An Open-label, Parallel-group Study to Assess the Effect of LIK066 on Urinary Glucose Excretion, Pharmacokinetics, Safety and Tolerability Following Multiple Dose Administration in Patients With Decreased Renal Function Compared to Subjects With Normal Renal Function
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2017
At a glance
- Drugs LIK 066 (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
- Sponsors Novartis Pharmaceuticals
- 16 Oct 2017 Planned End Date changed from 14 Feb 2018 to 7 Nov 2017.
- 16 Oct 2017 Planned primary completion date changed from 14 Feb 2018 to 7 Nov 2017.
- 11 May 2017 Status changed from not yet recruiting to recruiting.